Pharma Stock Jumps 22% from Day’s Low After Q4 Results and 50% Profit Growth Guidance

Synopsis: The share of this company rebounded after strong Q4 FY26 results, supported by robust revenue and profit growth, margin expansion, and a strong FY27 outlook with expected 50 percent earnings growth guidance.

The share of this company, which specializes in producing complex molecules and finished dosage formulations, including liquids, injectables, capsules, and oncology drugs, gained traction after a strong Q4.

With a market capitalization of Rs 2,052 crore, Kwality Pharmaceuticals Ltd’s share made a day high of Rs 2,051.20 per share, up by 22 percent from its day’s low of Rs 1,680 per share and is currently trading 9 percent up from its previous close. The share of the company delivered a return of 139 percent over the last year.

Results Overview

• QoQ View: The revenue from operations grew by 28 percent to Rs 157.1 crore in Q4 FY26 from Rs 123.4 crore in Q3 FY26, and EBITDA grew by 29 percent to Rs 38.8 crore in Q4 FY26 from Rs 30.0 crore in Q3 FY26. Accompanied by a net profit growth of 61 percent to Rs 25.3 crore in Q4 FY26 from Rs 16.0 crore in Q3 FY26.
• YoY View: The revenue from operations grew by 36.2 percent to Rs 157.1 crore in Q4 FY26 from Rs 115.6 crore in Q4 FY25, and EBITDA grew by 50.4 percent to Rs 38.8 crore in Q4 FY26 from Rs 25.8 crore in Q4 FY25. Accompanied by a net profit growth of 77.2 percent to Rs 25.3 crore in Q4 FY26 from Rs 14.5 crore in Q4 FY25.
• Fiscal Year Comparison: The revenue from operations grew by 36 percent to Rs 503.1 crore in FY26 from Rs 370.2 crore in FY25, and annual EBITDA grew by 47 percent to Rs 118.3 crore in FY26 from Rs 80.4 crore in FY25. Accompanied by an annual net profit growth of 72 percent to Rs 67.4 crore in FY26 from Rs 39.8 crore in FY25.

Robust Q4 perfomance

• Record Q4 and FY26 revenue performance: Kwality Pharmaceuticals reported its highest-ever quarterly revenue of Rs 157.11 crore in Q4 FY26, up 35.8 percent YoY from Rs 115.67 crore. For FY26, consolidated revenue increased nearly 36 percent YoY to Rs 503 crore from Rs 370 crore.
• Strong margin expansion and profitability growth. The company’s EBITDA margin improved to 24 percent in FY26 from 22 percent in FY25, supported by a better product mix and higher contribution from regulated markets. PAT surged around 69 percent YoY to Rs 67.34 crore, while PAT margin expanded to 13.4 percent.
• Global expansion and regulatory progress: Kwality Pharmaceuticals successfully cleared multiple international regulatory audits during FY26 and upgraded its ICRA credit rating to BBB+ from B+. The company also participated in over 15 global pharma exhibitions across LATAM, Africa, GCC, MENA, and Asia to strengthen its international presence.
• Biologics pipeline and FY27 outlook: The company accelerated investments in biologics and specialty therapeutics, including development work on multiple monoclonal antibodies and its biologic product Kwalipoieti. Management reiterated its FY27 guidance of Rs 650 crore revenue and Rs 100 crore PAT, which is 48.3 percent growth from FY26 PAT with potential upside from faster approvals and commercialization.

About the Company

Founded in 1983 and headquartered in Amritsar, Punjab, Kwality Pharmaceuticals Ltd is a rapidly growing Indian pharmaceutical manufacturer. The company specializes in complex generic molecules, supplying a vast portfolio of over 3,000 formulations spanning more than 25 therapeutic areas.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma Stock Jumps 22% from Day’s Low After Q4 Results and 50% Profit Growth Guidance appeared first on Trade Brains.